Sepsis remains one of the world’s deadliest medical emergencies, causing millions of deaths every year despite advances in intensive care medicine. The condition triggers an extreme immune response that can rapidly lead to organ failure, septic shock, and death if not treated quickly. Yet while cancer, cardiovascular disease, and neurological disorders often dominate medical research headlines and funding, sepsis continues to receive comparatively limited global attention. Biotech company Efferon is developing blood purification technologies designed to improve outcomes for patients with sepsis and systemic inflammation, and the company has now secured fresh funding to expand production and commercial operations across Europe.
Efferon has raised €2.5 million in a seed funding round led by private investors from the DACH region.
The investment will support European expansion of the company’s flagship hemoadsorption device, Efferon LPS, alongside growth in manufacturing capacity and infrastructure.
Developing Blood Purification Therapies
Efferon develops multimodal hemoadsorption therapeutic devices designed to remove harmful inflammatory mediators and endotoxins directly from the bloodstream.
Its product portfolio includes Efferon LPS, a blood purification cartridge combining endotoxin adsorption and cytokine removal capabilities, as well as Efferon NEO, a specialised version developed for pediatric and neonatal patients.
The company says these therapies are designed to support patients suffering from sepsis and septic shock by helping stabilise severe inflammatory responses more rapidly during intensive care treatment.
According to Efferon, use of its devices can help reduce intensive care unit costs by shortening time spent on mechanical ventilation and reducing the duration of intensive care treatment.
Addressing a Major Global Health Challenge
Sepsis occurs when the body’s immune response to infection becomes dysregulated, triggering widespread inflammation that can damage organs and tissues throughout the body.
Despite causing more than 11 million deaths annually worldwide, sepsis has historically received less research funding and public attention than many other major diseases.
Dima Romashin said the company’s mission extends beyond commercialising medical devices and focuses on elevating sepsis as a global healthcare priority.
Romashin said Efferon aims to push sepsis treatment and awareness higher on the international medical agenda while expanding access to advanced blood purification therapies.
Expanding Beyond Intensive Care
While Efferon’s current commercial focus centres on sepsis and septic shock treatment, the company believes systemic inflammation also plays a significant role across a broader range of chronic and age related diseases.
According to the company, its hemoadsorption platform could eventually support future applications beyond intensive care medicine by targeting inflammatory processes associated with other medical conditions.
The broader blood purification and immunomodulation market has attracted growing attention in recent years as researchers explore therapies capable of directly removing harmful inflammatory molecules from circulation.
Pediatric Approval Marks Major Milestone
Efferon recently received CE MDR certification for Efferon NEO, making it the first hemoadsorption device in Europe approved specifically for neonatal and pediatric patients with sepsis and septic shock.
The approval was supported by results from the multicentre LASSO NEO clinical study, which evaluated targeted endotoxin and cytokine removal in patients ranging from one month to 18 years old.
The company says the certification represents a significant milestone in expanding blood purification therapies into younger patient populations where treatment options remain limited.
Growing International Adoption
According to Efferon, its technology has already been used in more than 25,000 treatments across over 40 countries including Germany, the United Kingdom, Australia, and Saudi Arabia.
The newly secured funding will help finance construction of a new European Union production facility for Efferon LPS while expanding manufacturing capacity to meet growing demand.
As healthcare systems continue searching for more effective therapies for severe inflammatory conditions and critical care patients, companies developing advanced blood purification technologies are becoming an increasingly important part of the global intensive care and medical technology landscape.